Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp ...

I mean it's a national outrage that we spend more money on drugs like Aranesp and Procrit that up your red blood count. It's never saved a person's life. We spend more money on these anti-medics ...

Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...

Gratus Wealth Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 36.8% during the third quarter, ...

Aranesp. The latter two products reached ∼$3.3 billion in sales last year compared with Epogen's puny $2.5 billion! Second-generation products, of course, make a great deal of strategic sense.

Somerset Trust Co trimmed its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.6% in the third quarter, according to its ...

MK-2578, in phase 2 trials, was Merck's most advanced biosimilar—similar to Amgen's blockbuster Aranesp (darbepoetin alfa). “Other biosimilars counterparts will have to face [similarly] strict ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...